Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

Mathieu Bastard

7 ta ish

Epicentre Health Research

AkademScholarda batafsil koʻrsatkichlar

  1. Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study

    Elisabeth Sánchez-Padilla, Caroline Marquer, Stobdan Kalon +5

    Maqola20145 iqtibos
    ABI

  2. Revised Definitions of Multidrug-Resistant Tuberculosis Treatment Outcomes: Closer to the Reality?

    Mathieu Bastard, Maryline Bonnet, Philipp du Cros +9

    BoshqaTuberculosis Research and EpidemiologyAmerican Journal of Respiratory and Critical Care Medicine20151 iqtibos
    ABI

  3. Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)

    Maryline Bonnet, Mathieu Bastard, Philipp du Cros +7

    MaqolaTuberculosis Research and EpidemiologyEuropean Respiratory Journal20130 iqtibos
    ABI

  4. A multicentric cohort analysis of culture conversion and reversion in multidrug resistant tuberculosis (MDRTB) patients

    Cathy Hewison, Teshome Ashagre, Tigay Zinaida +7

    MaqolaTuberculosis Research and EpidemiologyEuropean Respiratory Journal20130 iqtibos
    ABI

  5. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study

    M. Bonnet, Mathieu Bastard, Philipp du Cros +9

    MaqolaTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20150 iqtibos
    ABI

  6. Reply: How Do the New Definitions for Multidrug-Resistant Tuberculosis Treatment Outcomes Really Perform?

    Mathieu Bastard, Maryline Bonnet, Philipp du Cros +9

    BoshqaTuberculosis Research and EpidemiologyAmerican Journal of Respiratory and Critical Care Medicine20150 iqtibos
    ABI

  7. Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study

    Mathieu Bastard, Elisabeth Sánchez-Padilla, Philipp du Cros +12

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyPLoS ONE20180 iqtibos
    ABI